Trial Profile
A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Birinapant (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- 14 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as funding was not secured
- 20 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 26 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.